Low willingness to vaccinate against herpes zoster in a Chinese metropolis

Lu, Xinya; Lu, Jia; Zhang, Felicia; Wagner, Abram L.; Zhang, Liping; Mei, Kewen; Guan, Bing; Lu, Yihan

doi:10.1080/21645515.2021.1960137

Cited by 14 publications

(25 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to a study conducted in China, we found that male participants were more likely to accept the HZV than female participants [ 26 ]. Our study provides information regarding the strong association of HZV willingness among patients with diabetes who are aware that immunocompromised individuals are at a higher risk of HZ infection and believe that the vaccine is effective.…”

Section: Discussioncontrasting

confidence: 99%

“…A wide range of variations have been noted in HZ vaccination coverage in different countries. A coverage rate of 24% was found in the USA among adults aged 60 years or older [ 23 ], and coverage rates of 9%, 11.9%, and 16.57% have been reported in South Korea, Texas, and China, respectively [ 24 , 25 , 26 ]. The uptake rate in the Netherlands has been reported as 58.1% [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acceptability of Herpes Zoster Vaccination among Patients with Diabetes: A Cross-Sectional Study in Saudi Arabia

et al. 2023

View full text Add to dashboard Cite

Background: Vaccines have recently been made available free of charge by the Saudi Ministry of Health for people 50 years or older. Diabetes mellitus (DM) increases herpes zoster (HZ) susceptibility, severity, serious complications, and negative impacts on underlying DM conditions, which are highly prevalent in Saudi Arabia. This study aimed to assess the acceptability of the HZ vaccination and its predictors among patients with diabetes in the Qassim region of Saudi Arabia. Methods: A cross-sectional study of patients with diabetes from a primary healthcare center in the Qassim region was conducted. Information was obtained on sociodemographic characteristics, history of herpes zoster infection, knowing someone who had had herpes zoster, past vaccinations, and factors influencing their intention to receive the HZ vaccination through a self-administered online questionnaire. Results: The median age (IQR) was 56 years (53–62). Overall, 25% (n = 104/410) of the participants reported their acceptability of the HZ vaccination, and the predictors were being male (AOR 2.01, 95% CI 1.01–4.00, p = 0.047), believing the HZ vaccine was effective (AOR 3.94, 95% CI 2.25–6.90, p < 0.001), and awareness that immunocompromised individuals are at a higher risk of contracting HZ (AOR 2.32, 95% CI 1.37–3.93, p = 0.002). A total of 74.2% (n = 227/306) of the participants reported their acceptability of the HZ vaccination if advised by their physician, and the predictors were being male (AOR 2.37, 95% CI 1.18–4.79, p = 0.016) and having a history of varicella vaccine uptake (AOR 4.50, 95% CI 1.02–19.86, p = 0.047). Conclusions: One-quarter of the participants were ready to accept the HZ vaccine, but this proportion significantly increased when the patients were advised by their physicians. The uptake rate can be improved with the involvement of healthcare providers and focused awareness campaigns about the effectiveness of the vaccine.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Acceptability of Herpes Zoster Vaccination among Patients with Diabetes: A Cross-Sectional Study in Saudi Arabia

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Another investigation used the aVHS to identify the main barriers to vaccine acceptance among medical students in Kazakhstan [38]. The aVHS was used to assess vaccination hesitancy against herpes zoster, influenza, and pneumonia among adults [39,40].…”

Section: Discussionmentioning

confidence: 99%

The Italian Version of the Adult Vaccine Hesitancy Scale (aVHS) for the Working-Age Population: Cross-Cultural Adaptation, Reliability, and Validity

Ledda

Costantino

Liberti³

et al. 2022

Vaccines

View full text Add to dashboard Cite

The adult Vaccine Hesitancy Scale (aVHS) is valid and reliable for evaluating attitudes toward vaccine preventable diseases (VPDs). The aim of the present study was to evaluate the cross-cultural adaptation, reliability, and validity of the Italian version of the aVHS. After cross-cultural adaptation of the aVHS, internal consistency (IC), intra-class correlation (ICC), and content validity (S-CVI) were evaluated through a survey on 160 workers. Results of the ICC were analyzed on questionnaires administered twice at a distance of two months and revealed a satisfactory reproducibility (0.87). The IC of the aVHS was assessed by the Cronbach alpha coefficient test, with a result of 0.94, demonstrating an excellent IC reliability. The S-CVI calculated for the total scale was 0.97. The aVHS is a valid and reliable tool for evaluating vaccine hesitancy toward adult vaccinations. We suggest the use of this scale in upcoming surveys on opinions and perceptions of adult vaccinations.

show abstract

“…Available data on VH for HZ vaccination are limited in the scientific literature but suggests that VH rates for this vaccine are higher than other vaccines such as COVID-19 and flu [ 13 , 14 ]. According to studies conducted in Italy in 2018 and in the United States in 2017, acceptance rates for HZ were around 20.7–22.6% and 17.8–46.6%, respectively [ 15 , 16 ], while even lower rates were reported in settings where the vaccine was not offered out-of-pocket [ 17 ]. In another recent study in the UK, the uptake rate for HZ found after a three-year extensive vaccination program was 58–72% among the targeted cohorts [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Adherence to Herpes Zoster (Shingles) Catch-Up Campaign at the Romagna Local Health Authority (Italy), a Multi-Center Retrospective Observational Study

et al. 2022

View full text Add to dashboard Cite

Herpes Zoster (shingles) is an infection that occurs when varicella-zoster virus reactivates from the latent state. Incidence and severity of Herpes Zoster disease increase with age. Antiviral drugs are the elective treatment; however, prevention of disease reactivation through effective and safe vaccines is available in Italy out-of-pocket from age 65 onwards. The Romagna Local Health Authority (northern Italy) administered catch-up vaccinations in March–May 2022 for immunizations not performed during the COVID-19 pandemic. In this study, adherence rates to the catch-up campaign and recall activities adopted in two centers were investigated. The uptakes for only the catch-up vaccinations were 11.4% and 12.4%. Having suffered from Herpes Zoster or having family members who suffered from it would not seem to be drivers of increased uptake. Although sending text-messages to all involved patients was the main motivation for vaccine uptake (85.7–95.1%), word of mouth and web/news advertising also contributed to adoption in Center No. 2. In both centers, the need for greater synergy between public health departments and general practitioners to engage their patients emerged, as did the need for additional recall measures. Studying the main drivers of vaccine hesitancy, especially at the local level, can help in targeting campaigns and catch-up activities in order to achieve widespread acceptance.

show abstract

Low willingness to vaccinate against herpes zoster in a Chinese metropolis

Cited by 14 publications

References 18 publications

Acceptability of Herpes Zoster Vaccination among Patients with Diabetes: A Cross-Sectional Study in Saudi Arabia

Acceptability of Herpes Zoster Vaccination among Patients with Diabetes: A Cross-Sectional Study in Saudi Arabia

The Italian Version of the Adult Vaccine Hesitancy Scale (aVHS) for the Working-Age Population: Cross-Cultural Adaptation, Reliability, and Validity

Adherence to Herpes Zoster (Shingles) Catch-Up Campaign at the Romagna Local Health Authority (Italy), a Multi-Center Retrospective Observational Study

Contact Info

Product

Resources

About